Post-earnings recap
Reported
Thu, Aug 13, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Ultragenyx Pharma is facing challenges, as evidenced by the EPS miss. The stock reacted negatively, dropping 2.28% in response to the disappointing results and lack of guidance. Investors may be concerned about the company's future performance without clear direction from management.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.83 | N/A | -33.44% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed caution regarding future performance. They highlighted ongoing challenges but did not provide detailed insights.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in meeting earnings expectations.